Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.
Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):82-91. doi: 10.1158/1055-9965.EPI-11-0836. Epub 2011 Nov 15.
Laboratory studies suggest that vitamin D may inhibit pancreatic cancer cell growth. However, epidemiologic studies of vitamin D and pancreatic cancer risk have been conflicting.
To determine whether prediagnostic levels of plasma 25-hydroxyvitamin D (25[OH]D; IDS Inc.; enzyme immunoassay) were associated with risk of pancreatic cancer, we conducted a pooled analysis of nested case-control studies with 451 cases and 1,167 controls from five cohorts through 2008. Median follow-up among controls was 14.1 years in Health Professionals Follow-Up Study (HPFS), 18.3 years in Nurses' Health Study (NHS), 25.3 years in Physicians' Health Study (PHS), 12.2 years in Women's Health Initiative-Observational Study (WHI), and 14.4 years in Women's Health Study (WHS). Logistic regression was used to compare the odds of pancreatic cancer by plasma level of 25(OH)D.
Mean plasma 25(OH)D was lower in cases versus controls (61.3 vs. 64.5 nmol/L, P = 0.005). In logistic regression models, plasma 25(OH)D was inversely associated with odds of pancreatic cancer. Participants in quintiles two through five had multivariable-adjusted ORs (95% confidence intervals) of 0.79 (0.56-1.10), 0.75 (0.53-1.06), 0.68 (0.48-0.97), and 0.67 (0.46-0.97; P(trend) = 0.03), respectively, compared with the bottom quintile. Compared with those with insufficient levels [25[OH]D, <50 nmol/L], ORs were 0.75 (0.58-0.98) for subjects with relative insufficiency [25[OH]D, 50 to <75 nmol/L] and 0.71 (0.52-0.97) for those with sufficient levels [25[OH]D, ≥ 75 nmol/L]. No increased risk was noted in subjects with 25(OH)D ≥100 nmol/L, as suggested in a prior study. In subgroup analyses, ORs for the top versus bottom quartile of 25(OH)D were 0.72 (0.48-1.08) for women, 0.73 (0.40-1.31) for men, and 0.73 (0.51-1.03) for Whites.
Among participants in five large prospective cohorts, higher plasma levels of 25(OH)D were associated with a lower risk for pancreatic cancer.
Low circulating 25(OH)D may predispose individuals to the development of pancreatic cancer.
实验室研究表明,维生素 D 可能抑制胰腺癌细胞的生长。然而,维生素 D 与胰腺癌风险的流行病学研究结果存在矛盾。
为了确定诊断前血浆 25-羟维生素 D(25[OH]D;IDS Inc.;酶联免疫吸附测定法)水平是否与胰腺癌风险相关,我们对五个队列的 451 例病例和 1167 例对照进行了嵌套病例对照研究的汇总分析,这些研究时间跨度为 2008 年。在健康专业人员随访研究(HPFS)中,对照者的中位随访时间为 14.1 年;在护士健康研究(NHS)中为 18.3 年;在医师健康研究(PHS)中为 25.3 年;在妇女健康倡议观察性研究(WHI)中为 12.2 年;在妇女健康研究(WHS)中为 14.4 年。使用 logistic 回归比较了不同血浆 25(OH)D 水平下胰腺癌的发病几率。
病例组的平均血浆 25(OH)D 水平低于对照组(61.3 与 64.5 nmol/L,P=0.005)。在多变量调整的 logistic 回归模型中,血浆 25(OH)D 与胰腺癌的发病几率呈负相关。25(OH)D 处于第二至第五五分位的参与者的多变量调整比值比(95%置信区间)分别为 0.79(0.56-1.10)、0.75(0.53-1.06)、0.68(0.48-0.97)和 0.67(0.46-0.97;P(趋势)=0.03),与最低五分位相比。与 25[OH]D 水平<50 nmol/L 的不足量患者相比,25[OH]D 水平为 50-<75 nmol/L 的相对不足量患者的比值比为 0.75(0.58-0.98),25[OH]D 水平≥75 nmol/L 的足量患者的比值比为 0.71(0.52-0.97)。先前的研究表明,25(OH)D 水平≥100 nmol/L 的患者中未观察到风险增加。在亚组分析中,25(OH)D 处于最高四分位与最低四分位的比值比为,女性为 0.72(0.48-1.08),男性为 0.73(0.40-1.31),白人患者为 0.73(0.51-1.03)。
在五个大型前瞻性队列的参与者中,较高的血浆 25(OH)D 水平与较低的胰腺癌风险相关。
低循环 25(OH)D 可能使个体易患胰腺癌。